Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 22 | 2013 | 734 | 2.210 |
Why?
|
| Hypolipidemic Agents | 14 | 2009 | 183 | 1.640 |
Why?
|
| Dyslipidemias | 7 | 2010 | 235 | 1.490 |
Why?
|
| Anticholesteremic Agents | 14 | 2009 | 239 | 1.460 |
Why?
|
| Coronary Artery Disease | 13 | 2014 | 849 | 1.380 |
Why?
|
| Heptanoic Acids | 6 | 2013 | 77 | 1.120 |
Why?
|
| Lipoproteins, HDL | 4 | 2012 | 96 | 1.090 |
Why?
|
| Atherosclerosis | 6 | 2012 | 929 | 1.080 |
Why?
|
| Pyrroles | 5 | 2013 | 184 | 1.010 |
Why?
|
| Simvastatin | 6 | 2009 | 76 | 0.990 |
Why?
|
| Coronary Disease | 10 | 2007 | 640 | 0.990 |
Why?
|
| Hyperlipidemias | 7 | 2005 | 181 | 0.900 |
Why?
|
| Azetidines | 4 | 2009 | 64 | 0.890 |
Why?
|
| Cholesterol, HDL | 8 | 2012 | 379 | 0.810 |
Why?
|
| Clinical Trials as Topic | 14 | 2008 | 1102 | 0.810 |
Why?
|
| Cholesterol, LDL | 15 | 2006 | 604 | 0.760 |
Why?
|
| Pravastatin | 5 | 2008 | 22 | 0.580 |
Why?
|
| Myocardial Infarction | 7 | 2008 | 980 | 0.510 |
Why?
|
| Hypercholesterolemia | 6 | 2005 | 230 | 0.470 |
Why?
|
| Coronary Artery Bypass | 5 | 2014 | 525 | 0.460 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2014 | 161 | 0.450 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2007 | 637 | 0.430 |
Why?
|
| Drug-Eluting Stents | 1 | 2014 | 63 | 0.420 |
Why?
|
| Hypolipoproteinemias | 1 | 2013 | 4 | 0.400 |
Why?
|
| Musculoskeletal Pain | 1 | 2013 | 16 | 0.400 |
Why?
|
| Oxidative Stress | 4 | 2012 | 756 | 0.400 |
Why?
|
| Muscle, Skeletal | 2 | 2013 | 972 | 0.390 |
Why?
|
| Diabetes Complications | 1 | 2014 | 194 | 0.390 |
Why?
|
| Cardiovascular Diseases | 4 | 2007 | 2036 | 0.380 |
Why?
|
| Rhabdomyolysis | 2 | 2003 | 35 | 0.370 |
Why?
|
| Cholesterol | 5 | 2004 | 535 | 0.370 |
Why?
|
| Niacin | 3 | 2009 | 51 | 0.360 |
Why?
|
| Myocardial Ischemia | 5 | 2002 | 299 | 0.360 |
Why?
|
| Inflammation | 5 | 2007 | 1420 | 0.350 |
Why?
|
| Arteriosclerosis | 3 | 2002 | 112 | 0.350 |
Why?
|
| Heart Failure | 7 | 2009 | 2289 | 0.350 |
Why?
|
| Hypertension | 4 | 2010 | 1301 | 0.340 |
Why?
|
| Hyperlipoproteinemia Type II | 3 | 2009 | 119 | 0.330 |
Why?
|
| Humans | 66 | 2014 | 126753 | 0.320 |
Why?
|
| Renin-Angiotensin System | 2 | 2001 | 98 | 0.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2002 | 210 | 0.300 |
Why?
|
| Lipids | 3 | 2009 | 550 | 0.290 |
Why?
|
| Lipoproteins, LDL | 2 | 2006 | 119 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2008 | 1184 | 0.270 |
Why?
|
| Diabetes Mellitus | 2 | 2008 | 873 | 0.270 |
Why?
|
| Risk Factors | 13 | 2010 | 10555 | 0.260 |
Why?
|
| Ezetimibe | 4 | 2009 | 94 | 0.260 |
Why?
|
| Inflammation Mediators | 1 | 2007 | 222 | 0.240 |
Why?
|
| Sympathetic Nervous System | 1 | 2005 | 55 | 0.240 |
Why?
|
| Angina, Unstable | 2 | 2005 | 49 | 0.240 |
Why?
|
| Aortic Valve Stenosis | 1 | 2009 | 334 | 0.230 |
Why?
|
| Tyrosine | 2 | 2002 | 146 | 0.220 |
Why?
|
| Drug Therapy, Combination | 6 | 2009 | 1137 | 0.220 |
Why?
|
| Cardiomyopathies | 2 | 2009 | 500 | 0.220 |
Why?
|
| Allylamine | 1 | 2004 | 8 | 0.210 |
Why?
|
| Homeostasis | 1 | 2008 | 689 | 0.210 |
Why?
|
| Pyridines | 2 | 2003 | 251 | 0.200 |
Why?
|
| Intestinal Absorption | 1 | 2004 | 170 | 0.200 |
Why?
|
| Energy Metabolism | 1 | 2008 | 761 | 0.200 |
Why?
|
| Insulin | 1 | 2008 | 1128 | 0.200 |
Why?
|
| Endothelium, Vascular | 4 | 2010 | 459 | 0.190 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2003 | 99 | 0.190 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2002 | 61 | 0.190 |
Why?
|
| Metabolic Syndrome | 1 | 2004 | 345 | 0.170 |
Why?
|
| Liver | 3 | 2008 | 1765 | 0.170 |
Why?
|
| Biological Transport | 2 | 2012 | 327 | 0.170 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2008 | 1352 | 0.170 |
Why?
|
| Myositis | 1 | 2001 | 100 | 0.160 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2000 | 27 | 0.160 |
Why?
|
| Prognosis | 4 | 2012 | 4772 | 0.160 |
Why?
|
| Obesity | 2 | 2008 | 2332 | 0.150 |
Why?
|
| Central Nervous System | 1 | 2000 | 272 | 0.140 |
Why?
|
| Lipoproteins, VLDL | 2 | 2009 | 53 | 0.140 |
Why?
|
| Neoplasms | 1 | 2013 | 2855 | 0.140 |
Why?
|
| Survival Rate | 4 | 2006 | 2101 | 0.140 |
Why?
|
| Stroke | 2 | 2003 | 1027 | 0.140 |
Why?
|
| Triglycerides | 5 | 2007 | 596 | 0.130 |
Why?
|
| Disease Progression | 5 | 2010 | 2109 | 0.130 |
Why?
|
| Male | 24 | 2014 | 62543 | 0.120 |
Why?
|
| Blood Coagulation | 2 | 2011 | 122 | 0.120 |
Why?
|
| Endocarditis | 1 | 1997 | 101 | 0.120 |
Why?
|
| Signal Transduction | 1 | 2008 | 4472 | 0.120 |
Why?
|
| Lipoproteins | 3 | 2009 | 183 | 0.110 |
Why?
|
| Female | 21 | 2014 | 68330 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2013 | 6214 | 0.110 |
Why?
|
| Multicenter Studies as Topic | 2 | 2005 | 290 | 0.100 |
Why?
|
| Coronary Circulation | 2 | 2008 | 189 | 0.100 |
Why?
|
| Fatty Acids, Monounsaturated | 3 | 1999 | 49 | 0.100 |
Why?
|
| Adrenergic beta-Antagonists | 3 | 2005 | 214 | 0.100 |
Why?
|
| Diuretics | 1 | 2013 | 153 | 0.100 |
Why?
|
| Lovastatin | 1 | 1992 | 27 | 0.100 |
Why?
|
| Insulin Resistance | 2 | 2008 | 665 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2012 | 3586 | 0.090 |
Why?
|
| Drug Interactions | 3 | 2000 | 240 | 0.090 |
Why?
|
| Double-Blind Method | 5 | 2009 | 1584 | 0.090 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2002 | 73 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2006 | 12546 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2065 | 0.090 |
Why?
|
| Indoles | 3 | 1999 | 199 | 0.090 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 422 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2005 | 442 | 0.080 |
Why?
|
| Heart Transplantation | 3 | 2005 | 866 | 0.080 |
Why?
|
| Vasoconstriction | 1 | 2010 | 92 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2001 | 3262 | 0.080 |
Why?
|
| Antioxidants | 1 | 2012 | 321 | 0.080 |
Why?
|
| Myocardium | 3 | 2005 | 847 | 0.080 |
Why?
|
| Lipoproteins, IDL | 1 | 2009 | 6 | 0.080 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 428 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2002 | 762 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2008 | 50 | 0.070 |
Why?
|
| Coronary Occlusion | 1 | 2008 | 31 | 0.070 |
Why?
|
| Cholestyramine Resin | 3 | 1996 | 13 | 0.070 |
Why?
|
| Resistin | 1 | 2007 | 30 | 0.070 |
Why?
|
| Acute-Phase Proteins | 1 | 2007 | 42 | 0.070 |
Why?
|
| Biomarkers | 3 | 2005 | 3222 | 0.070 |
Why?
|
| Adiponectin | 1 | 2007 | 124 | 0.060 |
Why?
|
| Gemfibrozil | 2 | 1996 | 4 | 0.060 |
Why?
|
| Middle Aged | 16 | 2013 | 27697 | 0.060 |
Why?
|
| Colestipol | 2 | 1996 | 6 | 0.060 |
Why?
|
| Parasympathetic Nervous System | 1 | 2005 | 14 | 0.060 |
Why?
|
| Leptin | 1 | 2007 | 218 | 0.060 |
Why?
|
| Apolipoprotein A-I | 1 | 2005 | 78 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2010 | 1312 | 0.060 |
Why?
|
| Acute Coronary Syndrome | 1 | 2008 | 239 | 0.060 |
Why?
|
| Colesevelam Hydrochloride | 1 | 2004 | 5 | 0.050 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 355 | 0.050 |
Why?
|
| Animals | 5 | 2008 | 33051 | 0.050 |
Why?
|
| Greece | 1 | 2003 | 11 | 0.050 |
Why?
|
| Scandinavian and Nordic Countries | 1 | 2002 | 4 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 1595 | 0.050 |
Why?
|
| Collagen | 2 | 2001 | 290 | 0.050 |
Why?
|
| Platelet Function Tests | 1 | 2002 | 39 | 0.050 |
Why?
|
| Time | 1 | 2002 | 94 | 0.050 |
Why?
|
| United Kingdom | 1 | 2003 | 234 | 0.050 |
Why?
|
| Risk Reduction Behavior | 1 | 2003 | 145 | 0.050 |
Why?
|
| Radiology, Interventional | 1 | 2002 | 35 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2002 | 165 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 1997 | 563 | 0.040 |
Why?
|
| Homocysteine | 1 | 2002 | 118 | 0.040 |
Why?
|
| Hot Temperature | 1 | 2002 | 136 | 0.040 |
Why?
|
| Cardiomegaly | 1 | 2001 | 119 | 0.040 |
Why?
|
| Cardiac Catheterization | 2 | 2002 | 629 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2002 | 275 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 1259 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 380 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 1999 | 31 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2001 | 679 | 0.040 |
Why?
|
| Isosorbide Dinitrate | 1 | 1998 | 4 | 0.040 |
Why?
|
| Diltiazem | 1 | 1998 | 14 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 1999 | 131 | 0.040 |
Why?
|
| Neovascularization, Physiologic | 1 | 2000 | 199 | 0.040 |
Why?
|
| Metoprolol | 1 | 1998 | 21 | 0.040 |
Why?
|
| Xylenes | 1 | 1998 | 13 | 0.040 |
Why?
|
| Premedication | 1 | 1998 | 37 | 0.040 |
Why?
|
| Bone Nails | 1 | 1998 | 26 | 0.040 |
Why?
|
| Aged | 8 | 2013 | 20344 | 0.040 |
Why?
|
| Fracture Fixation, Intramedullary | 1 | 1998 | 20 | 0.040 |
Why?
|
| Chlorhexidine | 1 | 1998 | 44 | 0.040 |
Why?
|
| Immunosuppressive Agents | 1 | 2002 | 649 | 0.040 |
Why?
|
| United States | 2 | 2004 | 11310 | 0.030 |
Why?
|
| Cocaine | 1 | 1999 | 208 | 0.030 |
Why?
|
| Anti-Infective Agents, Local | 1 | 1998 | 66 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 1999 | 198 | 0.030 |
Why?
|
| Fistula | 1 | 1998 | 51 | 0.030 |
Why?
|
| Prevalence | 1 | 2004 | 2591 | 0.030 |
Why?
|
| Tibial Fractures | 1 | 1998 | 64 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2000 | 485 | 0.030 |
Why?
|
| Adult | 11 | 2000 | 30410 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 202 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 53 | 0.030 |
Why?
|
| Clofibrate | 1 | 1996 | 1 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 1997 | 42 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1997 | 178 | 0.030 |
Why?
|
| Carotid Artery Diseases | 1 | 1997 | 133 | 0.030 |
Why?
|
| Fenofibrate | 1 | 1996 | 58 | 0.030 |
Why?
|
| Brain | 1 | 2008 | 3038 | 0.030 |
Why?
|
| Morbidity | 1 | 1997 | 245 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 533 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2002 | 5114 | 0.030 |
Why?
|
| Probucol | 1 | 1994 | 1 | 0.030 |
Why?
|
| Clofibric Acid | 1 | 1994 | 3 | 0.030 |
Why?
|
| Lipoprotein(a) | 1 | 1996 | 133 | 0.030 |
Why?
|
| Fibric Acids | 1 | 1994 | 7 | 0.030 |
Why?
|
| Incidence | 1 | 2002 | 3251 | 0.030 |
Why?
|
| Pulmonary Artery | 1 | 1998 | 442 | 0.030 |
Why?
|
| Time Factors | 6 | 2005 | 6134 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 1997 | 785 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 1998 | 559 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 1997 | 525 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2002 | 4954 | 0.020 |
Why?
|
| Etanercept | 2 | 2002 | 44 | 0.020 |
Why?
|
| Heart-Assist Devices | 1 | 2000 | 1045 | 0.020 |
Why?
|
| Coronary Angiography | 3 | 1999 | 453 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 5941 | 0.020 |
Why?
|
| Echocardiography | 1 | 1997 | 1114 | 0.020 |
Why?
|
| Acyl Coenzyme A | 1 | 1991 | 23 | 0.020 |
Why?
|
| Naphthalenes | 1 | 1991 | 38 | 0.020 |
Why?
|
| Age Factors | 1 | 1997 | 2789 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1779 | 0.020 |
Why?
|
| Adolescent | 2 | 2005 | 20002 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 1997 | 1162 | 0.020 |
Why?
|
| Cardiovascular Agents | 2 | 1998 | 85 | 0.020 |
Why?
|
| Adenosine | 2 | 1998 | 126 | 0.020 |
Why?
|
| Combined Modality Therapy | 2 | 2005 | 1220 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 1997 | 2507 | 0.010 |
Why?
|
| HIV Infections | 1 | 1997 | 1951 | 0.010 |
Why?
|
| Mice | 1 | 2001 | 17596 | 0.010 |
Why?
|
| Hypertrophy | 1 | 2005 | 101 | 0.010 |
Why?
|
| Infliximab | 1 | 2002 | 65 | 0.010 |
Why?
|
| Hematologic Agents | 1 | 2001 | 6 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 131 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 2001 | 20 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2013 | 3066 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1992 | 6668 | 0.010 |
Why?
|
| Systole | 1 | 2001 | 193 | 0.010 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2001 | 144 | 0.010 |
Why?
|
| Myocarditis | 1 | 2001 | 124 | 0.010 |
Why?
|
| Organ Size | 1 | 2001 | 429 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 406 | 0.010 |
Why?
|
| Child | 1 | 2000 | 25101 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2005 | 609 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2002 | 445 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2013 | 17005 | 0.010 |
Why?
|
| Apolipoproteins | 1 | 1999 | 70 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2000 | 207 | 0.010 |
Why?
|
| Cardiac Output, Low | 1 | 1999 | 62 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1998 | 98 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1998 | 238 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 1597 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 1999 | 239 | 0.010 |
Why?
|
| Rabbits | 1 | 1998 | 614 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 1997 | 5 | 0.010 |
Why?
|
| Radionuclide Angiography | 1 | 1997 | 3 | 0.010 |
Why?
|
| Random Allocation | 1 | 1998 | 415 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2001 | 553 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2001 | 761 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 988 | 0.010 |
Why?
|
| Lipolysis | 1 | 1996 | 73 | 0.010 |
Why?
|
| Radiography | 1 | 1998 | 752 | 0.010 |
Why?
|
| Postprandial Period | 1 | 1996 | 85 | 0.010 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 1999 | 359 | 0.010 |
Why?
|
| Cytokines | 1 | 2001 | 1320 | 0.010 |
Why?
|
| Survival Analysis | 1 | 1999 | 1495 | 0.010 |
Why?
|
| Algorithms | 1 | 2002 | 1633 | 0.010 |
Why?
|
| Fasting | 1 | 1996 | 300 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1996 | 759 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1998 | 1398 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1997 | 767 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2001 | 1705 | 0.010 |
Why?
|
| Quality of Life | 1 | 2002 | 2029 | 0.010 |
Why?
|
| Genotype | 1 | 1997 | 2595 | 0.010 |
Why?
|
| Placebos | 1 | 1991 | 225 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1998 | 4429 | 0.000 |
Why?
|
| Severity of Illness Index | 1 | 1994 | 2975 | 0.000 |
Why?
|